CURRENT
ISSUE
1572
The FDA has approved Inbrija (Acorda), an orally inhaled dry-powder formulation of levodopa, for intermittent treatment of "off" episodes in patients with Parkinson's disease (PD) being treated with carbidopa/levodopa (Sinemet, and others)....  Continue reading
More from Issue 1572
Previous Issue: 1571      May 6, 2019
Coming Soon
Drugs for Psoriasis
Romosozumab (Evenity) for Postmenopausal Osteoporosis
Prucalopride (Motegrity) for Chronic Idiopathic Constipation
Risankizumab (Skyrizi) - A New IL-23 Antagonist for Plaque Psoriasis
Tafenoquine for Malaria
Search
Subscribe
Conversation
Follow us  facebook        Email Alerts
 Tweets
FROM
ISSUE
1572
The FDA has approved omadacycline (Nuzyra – Paratek), a semisynthetic tetracycline derivative, for once-daily IV and oral treatment of community-acquired bacterial pneumonia (CAP) and acute bacterial skin and skin structure infections (ABSSSIs) in adults. ... Continue reading